WALTHAM, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Great Elm Group, Inc. (“we,” “us,” “our,” “GEG,” or “Great Elm”), (NASDAQ: GEG), a diversified holding company, today announced financial results for its fiscal third quarter ended March 31, 2022.
Acquisition of Monomoy REIT Management Agreements for $10 million
- Transformative transaction for GEG’s Investment Management Business detailed in a separate press release issued today
- Furthers GEG’s Strategy of Adding a Long-Duration Capital Vehicle More Than Doubling AUM and Leveraging GEG’s Resources and Tax Attributes
- Transaction Contemplates Growth Investment into Monomoy REIT of up to $30 Million
- Acquisition was Unanimously Approved by GEG’s disinterested Directors and special committee
Filed S-1 Registration Statement for a Senior Unsecured Note offering
Fiscal 2022 Third Quarter Operating and Financial Highlights
(All comparisons versus the prior-year period unless otherwise noted)
Consolidated:
- Consolidated revenue for the third quarter was $16.6 million, compared to $13.8 million.
- Consolidated net loss from continuing operations for the third quarter was $6.1 million, compared to net loss from continuing operations of $2.8 million.
- Consolidated Adjusted EBITDA for the third quarter was $1.0 million, compared to $2.2 million.
- As of June 30, 2021, we had approximately $952 million of net operating loss (NOL) carryforwards for federal income tax purposes.
Investment Management (IM):
- IM grew total revenue for the third quarter by 35.7% to $1.0 million, compared to $0.7 million.
- IM net loss for the third quarter was $4.0 million, compared to a net loss of $0.7 million.
- IM recognized Adjusted EBITDA of ($0.4) million for the third quarter, compared to approximately breakeven for the prior-year period.
Operating Companies:
- Durable Medical Equipment (DME) grew total revenue for the third quarter by 19.2% to $15.6 million, compared to $13.1 million, driven by strong resupply sales despite challenging pandemic-related conditions.
- DME net loss for the third quarter was $6.6 million, compared to a net loss of $5.1 million. These losses include $5.6 million and $4.8 million, respectively, in intercompany charges related to the valuation of an embedded derivative that eliminates in consolidation.
- DME Adjusted EBITDA for the third quarter was $2.5 million, compared to $3.4 million. Exclusive of CARES Act stimulus received in the prior-year period, this represents an improvement of $1.4 million.
- DME total revenue, net income and Adjusted EBITDA for the trailing 12 month period ended March 31, 2022 were $62.3 million, $2.3 million and $14.6 million, respectively, compared to $56.2 million, ($5.6) million and $15.0 million.
Management Commentary
Peter A. Reed, Chief Executive Officer, stated, “We have taken steps to execute on our strategy of growing the management of long duration capital vehicles. Today’s announcement of the Monomoy transaction exemplifies this strategy. In addition, we have taken steps to grow GECC and its specialty finance platform, including the acquisition of Sterling Commercial Credit in the quarter. Our financial results for the fiscal third quarter of 2022 reinforced the benefits of our unique and diversified business model, spanning long-term investments in high-quality, growing operating companies in addition to our differentiated investment management platform. Our investment in DME continues to perform well despite challenging supply chain conditions.”
Alignment of Interest
A distinct attribute of Great Elm is the particularly strong alignment of interest among shareholders and the employees, directors, and other insiders of Great Elm. As of March 31, 2022, Great Elm’s employees and directors (including funds under their management) collectively own or manage approximately 30% of GEG’s total outstanding shares.
Financial Review
Discussion of Financial Results by Segment for the Fiscal Quarter ended March 31, 2022
Great Elm is a holding company with two operating segments: Operating Companies and Investment Management, with General Corporate representing unallocated costs and activity to arrive at consolidated operations.
Investment Management
During the three months ended March 31, 2022, IM reported total revenue of $1.0 million, compared to $0.7 million during the same period in the prior year. Revenue for the quarter was higher due to an increase in the average assets on which such fees are calculated through growth of GECC and our private fund GESOF, which was launched in February 2021.
During the three months ended March 31, 2022, IM recognized a net loss of $4.0 million, compared to a net loss of $0.7 million during the same period in the prior year. The net loss increased primarily due to higher unrealized losses on our investment in GECC common shares during the period. We mark-to-market our investment in GECC and underlying investments of consolidated funds by reference to the closing price of related investments on Nasdaq or other exchanges, as applicable, as of each period end.
During the three months ended March 31, 2022, IM recognized Adjusted EBITDA of ($0.4) million compared to approximately breakeven for the same period in the prior year. Increased revenue was more than offset by higher selling, general and administrative expenses due to an increase in allocated payroll costs, bonus accruals and consulting fees.
Operating Companies
During the three months ended March 31, 2022, DME reported $15.6 million in total revenue, compared to $13.1 million during the same period in the prior year. The increase in revenue was primarily attributable to contributions from the previously acquisitions of AMPM in March 2021 and of MedOne in August 2021. Revenue continues to be impacted by supply chain issues, though our DME business maintains a large backlog of patients seeking PAP treatments.
During the three months ended March 31, 2022, DME recognized a net loss of $6.6 million, compared to net loss of $5.1 million for the same period in the prior year. These losses include charges of $5.6 million and $4.8 million, respectively, related to changes in value of an embedded derivative on an intercompany instrument held by the Corporate segment, which eliminate in consolidation. Moreover, year-over-year comparisons were impacted by meaningful Employee Retention Tax Credits in the prior period as the prior period includes $2.3 million in benefits received under the CARES Act. Excluding these credits, segment profitability significantly improved versus the prior-year quarter.
Normalized for these items, the remaining improvement of $1.6 million in net loss compared to the same period in the prior year is attributed largely due to revenue growth combined with ongoing expense management.
During the three months ended March 31, 2022, DME Adjusted EBITDA was $2.5 million, compared to $3.4 million in the prior-year period. As noted, the prior period includes $2.3 million in benefits received under the CARES Act, whereas no such benefit was received in the current period.
General Corporate
During the three months ended March 31, 2022, General Corporate recognized $0.2 million in revenue, approximately unchanged from the same period in the prior year. Revenue at General Corporate consists of management fees charged to subsidiaries and eliminate in consolidation.
During the three months ended March 31, 2022, General Corporate recognized net income from continuing operations of $4.5 million, compared to net income from continuing operations of $3.0 million during the same period in the prior year. $0.8 million of the year-over-year variance can be attributed to the change in value of an embedded derivative on an intercompany instrument issued by the Operating Companies segment, which eliminates in consolidation. The remaining improvement is primarily related to dividends and unrealized gains from our existing investment in Monomoy REIT.
During the three months ended March 31, 2022, General Corporate recognized ($1.2) million of Adjusted EBITDA, approximately unchanged from Adjusted EBITDA of ($1.2) million during the same period in the prior year.
Fiscal 2022 Third Quarter Conference Call & Webcast Information
| When: | Friday, May 6, 2022, 9:00 a.m. Eastern Time (ET) | |
| Call: | All interested parties are invited to participate in the conference call by dialing +1 (888) 440-4537; international callers should dial +1 (646) 960-0669. Participants should enter the Conference ID 2595129 when asked. | |
| Webcast: | The conference call will be webcast simultaneously and can be accessed at the following link: https://events.q4inc.com/attendee/622762233. For a copy of the slide presentation accompanying the conference call, please visit: https://www.greatelmgroup.com/events-and-presentations. | |
About Great Elm Group, Inc.
Great Elm Group, Inc. (NASDAQ: GEG) is a publicly-traded holding company that is building a business across two operating verticals: Operating Companies and Investment Management. Great Elm Group, Inc.’s website can be found at www.greatelmgroup.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements in this press release that are “forward-looking” statements, including statements regarding revenue, Adjusted EBITDA, expected growth, profitability, acquisition opportunities and outlook involve risks and uncertainties that may individually or collectively impact the matters described herein. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and represent Great Elm’s assumptions and expectations in light of currently available information. These statements involve risks, variables and uncertainties, and Great Elm’s actual performance results may differ from those projected, and any such differences may be material. For information on certain factors that could cause actual events or results to differ materially from Great Elm’s expectations, please see Great Elm’s filings with the SEC, including its most recent annual report on Form 10-K and subsequent reports on Forms 10-Q and 8-K. Additional information relating to Great Elm’s financial position and results of operations is also contained in Great Elm’s annual and quarterly reports filed with the SEC and available for download at its website www.greatelmgroup.com or at the SEC website www.sec.gov.
Please note that previously reported amounts below have been recast to 1) reflect the operations of our real estate business as discontinued operations; 2) reflect the full retrospective adoption of ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity; and 3) conform with current segment organization.
Non-GAAP Financial Measures
The SEC has adopted rules to regulate the use in filings with the SEC, and in public disclosures, of financial measures that are not in accordance with US GAAP, such as adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”). Adjusted EBITDA is derived from methodologies other than in accordance with US GAAP. Great Elm believes that Adjusted EBITDA is an important measure for investors to use in evaluating Great Elm’s businesses. In addition, Great Elm’s management reviews Adjusted EBITDA as they evaluate acquisition opportunities.
Adjusted EBITDA has limitations as an analytical tool, and you should not consider it either in isolation from, or as a substitute for, analyzing Great Elm’s results as reported under US GAAP. Non-GAAP financial measures reported by Great Elm may not be comparable to similarly titled amounts reported by other companies.
Included in the financial tables below is a reconciliation of Adjusted EBITDA to the most directly comparable US GAAP financial measure, net income.
Investor Relations Contact:
Michael Kim / Garrett Edson
investorrelations@greatelmcap.com
Great Elm Group, Inc.
Condensed Consolidated Balance Sheets (Unaudited)
Dollar amounts in thousands (except per share data)
| ASSETS | March 31, 2022 | June 30, 2021 | ||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 22,746 | $ | 24,382 | ||||
| Accounts receivable | 7,684 | 6,518 | ||||||
| Related party receivables | 1,392 | 1,665 | ||||||
| Investments, at fair value (cost $44,845 and $45,326, respectively) | 19,160 | 24,044 | ||||||
| Inventories | 949 | 1,066 | ||||||
| Prepaid and other current assets | 1,007 | 3,791 | ||||||
| Assets of Consolidated Funds | ||||||||
| Investments, at fair value (cost $11,726 and $26,814, respectively) | 11,340 | 26,490 | ||||||
| Prepaid expenses and other assets | 2,708 | 578 | ||||||
| Total current assets | 65,586 | 88,534 | ||||||
| Property and equipment, net | 613 | 981 | ||||||
| Equipment held for rental, net | 6,810 | 7,391 | ||||||
| Identifiable intangible assets, net | 7,733 | 8,928 | ||||||
| Goodwill | 52,463 | 50,536 | ||||||
| Right of use assets | 4,024 | 5,241 | ||||||
| Other assets | 236 | 258 | ||||||
| Total assets | $ | 137,465 | $ | 161,869 | ||||
| LIABILITIES, NON-CONTROLLING INTEREST AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 5,635 | $ | 5,521 | ||||
| Accrued expenses and other liabilities | 6,044 | 6,955 | ||||||
| Deferred revenue | 1,420 | 4,438 | ||||||
| Current portion of lease liabilities | 1,663 | 1,920 | ||||||
| Current portion of capitalized equipment financing | 2,711 | 1,974 | ||||||
| Liabilities of Consolidated Funds- accrued expenses and other | 93 | 12,197 | ||||||
| Total current liabilities | 17,566 | 33,005 | ||||||
| Lease liabilities, net of current portion | 2,587 | 3,596 | ||||||
| Convertible notes (face value $35,205 and $34,346, respectively, including $16,637 and $16,231, respectively, held by related parties) | 34,278 | 33,333 | ||||||
| Equipment financing debt, net of current portion | - | 67 | ||||||
| Redeemable preferred stock of subsidiaries (held by related parties, face value $37,018) | 35,694 | 35,529 | ||||||
| Other liabilities | 360 | 915 | ||||||
| Total liabilities | 90,485 | 106,445 | ||||||
| Commitments and Contingencies (Note 18) | ||||||||
| Contingently redeemable non-controlling interest | 2,262 | 2,639 | ||||||
| Stockholders' equity | ||||||||
| Preferred stock, $0.001 par value; 5,000,000 authorized and zero outstanding | - | - | ||||||
| Common stock, $0.001 par value; 350,000,000 shares authorized and 27,464,767 shares issued and 26,963,203 outstanding at March 31, 2022; and 26,613,913 shares issued and 25,948,100 outstanding at June 30, 2021 | 27 | 26 | ||||||
| Additional paid-in-capital | 3,309,704 | 3,307,613 | ||||||
| Accumulated deficit | (3,274,750 | ) | (3,264,403 | ) | ||||
| Total Great Elm Group, Inc. stockholders' equity | 34,981 | 43,236 | ||||||
| Non-controlling interests | 9,737 | 9,549 | ||||||
| Total stockholders' equity | 44,718 | 52,785 | ||||||
| Total liabilities, non-controlling interest and stockholders' equity | $ | 137,465 | $ | 161,869 | ||||
Great Elm Group, Inc.
Condensed Consolidated Statements of Operations (Unaudited)
Dollar amounts in thousands (except per share data)
| For the three months ended March 31, | For the nine months ended March 31, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenues: | ||||||||||||||||
| Durable medical equipment sales and services revenue | $ | 10,359 | $ | 8,606 | $ | 30,712 | $ | 27,363 | ||||||||
| Durable medical equipment rental income | 5,275 | 4,511 | 16,205 | 14,907 | ||||||||||||
| Investment management revenues | 988 | 728 | 2,992 | 2,261 | ||||||||||||
| Total revenues | 16,622 | 13,845 | 49,909 | 44,531 | ||||||||||||
| Operating costs and expenses: | ||||||||||||||||
| Cost of durable medical equipment sold and services | 4,362 | 3,806 | 12,731 | 12,716 | ||||||||||||
| Cost of durable medical equipment rentals(1) | 1,708 | 1,657 | 5,292 | 5,193 | ||||||||||||
| Durable medical equipment other operating expenses(2) | 8,758 | 6,084 | 23,551 | 21,834 | ||||||||||||
| Investment management expenses | 1,592 | 904 | 4,748 | 2,546 | ||||||||||||
| Depreciation and amortization | 517 | 618 | 1,631 | 1,799 | ||||||||||||
| Selling, general and administrative(3) | 1,582 | 1,854 | 4,620 | 4,582 | ||||||||||||
| Expenses of Consolidated Funds | 42 | 19 | 139 | 27 | ||||||||||||
| Total operating costs and expenses | 18,561 | 14,942 | 52,712 | 48,697 | ||||||||||||
| Operating loss | (1,939 | ) | (1,097 | ) | (2,803 | ) | (4,166 | ) | ||||||||
| Dividends and interest income | 642 | 554 | 1,939 | 2,408 | ||||||||||||
| Net realized and unrealized (loss) gain on investments | (3,220 | ) | (1,112 | ) | (5,055 | ) | (454 | ) | ||||||||
| Net realized and unrealized gain (loss) on investments of Consolidated Funds | (284 | ) | 155 | (279 | ) | 221 | ||||||||||
| Interest expense | (1,354 | ) | (1,361 | ) | (4,078 | ) | (3,607 | ) | ||||||||
| Loss on extinguishment of debt | - | - | - | (1,866 | ) | |||||||||||
| Other income, net | - | - | 2 | 30 | ||||||||||||
| Loss from continuing operations, before income taxes | (6,155 | ) | (2,861 | ) | (10,274 | ) | (7,434 | ) | ||||||||
| Income tax benefit (expense) | 20 | 43 | 86 | (6 | ) | |||||||||||
| Loss from continuing operations | (6,135 | ) | (2,818 | ) | (10,188 | ) | (7,440 | ) | ||||||||
| Discontinued operations: | ||||||||||||||||
| Income from discontinued operations, net of tax | - | 73 | - | 211 | ||||||||||||
| Net loss | $ | (6,135 | ) | $ | (2,745 | ) | $ | (10,188 | ) | $ | (7,229 | ) | ||||
| Less: net income (loss) attributable to non-controlling interest, continuing operations | (226 | ) | (173 | ) | 159 | (907 | ) | |||||||||
| Less: net income attributable to non-controlling interest, discontinued operations | - | 15 | - | 45 | ||||||||||||
| Net loss attributable to Great Elm Group, Inc. | $ | (5,909 | ) | $ | (2,587 | ) | $ | (10,347 | ) | $ | (6,367 | ) | ||||
| Basic and diluted income (loss) per share from: | ||||||||||||||||
| Continuing operations | $ | (0.22 | ) | $ | (0.10 | ) | $ | (0.38 | ) | $ | (0.25 | ) | ||||
| Discontinued operations | - | 0.00 | - | (0.00 | ) | |||||||||||
| Net loss | $ | (0.22 | ) | $ | (0.10 | ) | $ | (0.38 | ) | $ | (0.25 | ) | ||||
| Weighted average shares outstanding | ||||||||||||||||
| Basic | 26,842 | 25,757 | 26,963 | 25,669 | ||||||||||||
| Diluted | 26,842 | 25,757 | 26,963 | 25,669 | ||||||||||||
| (1) Includes depreciation expense of: | 1,575 | 1,478 | 4,860 | 4,683 | ||||||||||||
| (2) Net of CARES Act Stimulus of: | - | 2,275 | 2,321 | 2,275 | ||||||||||||
| (3) Net of CARES Act Stimulus of: | - | - | 84 | - | ||||||||||||
Great Elm Group, Inc.
Reconciliation from EBITDA to Adjusted EBITDA - Quarterly
Dollar amounts in thousands (except per share data)
| . | ||||||||||||||||||
| For the three months ended March 31, 2022 | ||||||||||||||||||
| $ in thousands | Durable Medical Equipment | Investment Management | General Corporate | Consolidated | ||||||||||||||
| EBITDA: | ||||||||||||||||||
| Net income (loss) from continuing operations - GAAP | $ | (6,620 | ) | $ | (3,981 | ) | $ | 4,466 | $ | (6,135 | ) | |||||||
| Interest expense | 1,269 | 24 | 1,263 | 2,556 | ||||||||||||||
| Interest income from preferred stock | - | - | (1,202 | ) | (1,202 | ) | ||||||||||||
| Depreciation & amortization | 2,003 | 89 | - | 2,092 | ||||||||||||||
| Tax expense (benefit) | - | - | (20 | ) | (20 | ) | ||||||||||||
| EBITDA | (3,348 | ) | (3,868 | ) | 4,507 | (2,709 | ) | |||||||||||
| Adjusted EBITDA | ||||||||||||||||||
| Non-cash compensation | - | 262 | 316 | 578 | ||||||||||||||
| Change in contingent consideration | 68 | - | - | 68 | ||||||||||||||
| Dividend income | - | (548 | ) | (96 | ) | (644 | ) | |||||||||||
| (Gains) / losses on investments | - | 3,770 | (266 | ) | 3,504 | |||||||||||||
| Other (income) expense | 5,612 | - | (5,612 | ) | - | |||||||||||||
| Transaction and integration related costs (2) | 63 | - | 92 | 155 | ||||||||||||||
| DME management and monitoring fees | 117 | - | (117 | ) | - | |||||||||||||
| Adjusted EBITDA | $ | 2,512 | $ | (384 | ) | $ | (1,176 | ) | $ | 952 | ||||||||
| For the three months ended March 31, 2021 | |||||||||||||||||
| $ in thousands | Durable Medical Equipment | Investment Management (1) | General Corporate (1) | Consolidated | |||||||||||||
| EBITDA: | |||||||||||||||||
| Net income (loss) from continuing operations - GAAP | $ | (5,059 | ) | $ | (732 | ) | $ | 2,973 | $ | (2,818 | ) | ||||||
| Interest expense | 1,280 | 25 | 1,287 | 2,592 | |||||||||||||
| Interest income from preferred stock | - | - | (1,168 | ) | (1,168 | ) | |||||||||||
| Depreciation & amortization | 1,986 | 109 | 1 | 2,096 | |||||||||||||
| Tax expense (benefit) | - | - | (43 | ) | (43 | ) | |||||||||||
| EBITDA | (1,793 | ) | (598 | ) | 3,050 | 659 | |||||||||||
| Adjusted EBITDA | |||||||||||||||||
| Non-cash compensation | - | 181 | 470 | 651 | |||||||||||||
| GECC dividend income | - | (554 | ) | - | (554 | ) | |||||||||||
| GECC unrealized (gains) / losses | - | 984 | - | 984 | |||||||||||||
| Other (income) expense | 4,795 | - | (4,795 | ) | - | ||||||||||||
| Transaction and integration related costs (2) | 380 | - | 155 | 535 | |||||||||||||
| DME management and monitoring fees | 46 | - | (46 | ) | - | ||||||||||||
| Adjusted EBITDA | $ | 3,428 | $ | 13 | $ | (1,166 | ) | $ | 2,275 | ||||||||
| For the nine months ended March 31, 2022 | ||||||||||||||||
| $ in thousands | Durable Medical Equipment | Investment Management | General Corporate | Consolidated | ||||||||||||
| EBITDA: | ||||||||||||||||
| Net income (loss) from continuing operations - GAAP | $ | (3,601 | ) | $ | (6,752 | ) | $ | 165 | $ | (10,188 | ) | |||||
| Interest expense | 3,845 | 72 | 3,801 | 7,718 | ||||||||||||
| Interest income on preferred stock | - | - | (3,640 | ) | (3,640 | ) | ||||||||||
| Depreciation & amortization | 6,185 | 306 | 1 | 6,492 | ||||||||||||
| Tax expense (benefit) | - | - | (86 | ) | (86 | ) | ||||||||||
| EBITDA | $ | 6,429 | $ | (6,374 | ) | $ | 241 | $ | 296 | |||||||
| Adjusted EBITDA | ||||||||||||||||
| Non-cash compensation | - | 1,604 | 968 | 2,572 | ||||||||||||
| Change in contingent consideration | (380 | ) | - | - | (380 | ) | ||||||||||
| Dividend income | - | (1,651 | ) | (288 | ) | (1,939 | ) | |||||||||
| (Gains) / Losses on investments | - | 6,130 | (796 | ) | 5,334 | |||||||||||
| Other (income) expense | 3,468 | - | (3,470 | ) | (2 | ) | ||||||||||
| Transaction and integration costs (2) | 458 | - | 311 | 769 | ||||||||||||
| DME management and monitoring fees | 307 | - | (307 | ) | - | |||||||||||
| Adjusted EBITDA | $ | 10,282 | $ | (291 | ) | $ | (3,341 | ) | $ | 6,650 | ||||||
| For the nine months ended March 31, 2021 | |||||||||||||||||
| $ in thousands | Durable Medical Equipment | Investment Management (1) | General Corporate (1) | Consolidated | |||||||||||||
| EBITDA: | |||||||||||||||||
| Net income (loss) from continuing operations - GAAP | $ | (8,395 | ) | $ | 1,415 | $ | (459 | ) | $ | (7,439 | ) | ||||||
| Interest expense | 2,676 | 76 | 2,086 | 4,838 | |||||||||||||
| Interest income on preferred stock | - | - | (1,168 | ) | (1,168 | ) | |||||||||||
| Depreciation & amortization | 6,116 | 364 | 2 | 6,482 | |||||||||||||
| Tax expense (benefit) | - | - | 6 | 6 | |||||||||||||
| EBITDA | 397 | 1,855 | 467 | 2,718 | |||||||||||||
| Adjusted EBITDA | |||||||||||||||||
| Non-cash compensation | - | 572 | 793 | 1,365 | |||||||||||||
| Change in contingent consideration | - | - | - | - | |||||||||||||
| Dividend income | - | (2,400 | ) | - | (2,400 | ) | |||||||||||
| (Gains) / losses on investments | - | 260 | - | 260 | |||||||||||||
| Other (income) expense | 4,765 | - | (4,795 | ) | (30 | ) | |||||||||||
| Transaction and integration related costs (2) | 780 | - | 417 | 1,197 | |||||||||||||
| Extinguishment of debt | 1,866 | 1,866 | |||||||||||||||
| Location closure | 54 | - | - | 54 | |||||||||||||
| DME management and monitoring fees | 224 | - | (182 | ) | 42 | ||||||||||||
| Adjusted EBITDA | $ | 8,086 | $ | 287 | $ | (3,300 | ) | $ | 5,072 | ||||||||
| (1) Previously reported prior year amounts have been recast to reflect the full retrospective adoption of ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity; and to conform with current segment organization. | |||||||||||||||||
| (2) Transaction and integration related costs include costs to acquire and integrate acquired businesses. | |||||||||||||||||
